An integrated approach to identify normal tissue expression of targets for antibody-drug conjugates: Case study of TENB2

British Journal of Pharmacology

Volumn 168, Issue 2, 2013, Pages 445-457

  Boswell, C Andrew ^a   Mundo, Eduardo E ^a   Firestein, Ron ^a   Zhang, Crystal ^a   Mao, Weiguang ^a   Gill, Herman ^a   Young, Cynthia ^a   Ljumanovic, Nina ^a   Stainton, Shannon ^a   Ulufatu, Sheila ^a   Fourie, Aimee ^a   Kozak, Katherine R ^a   Fuji, Reina ^a   Polakis, Paul ^a   Khawli, Leslie A ^a   Lin, Kedan ^a  

^a GENENTECH INC   (United States)

Author keywords

antibody drug conjugates; ELISA; indium 111 DOTA; prostate cancer; TENB2; tissue distribution

Indexed keywords

ANTIBODY CONJUGATE; INDIUM 111; IODINE 125; MONOCLONAL ANTIBODY; PROTEOCHONDROITIN SULFATE; TETRAXETAN; TRANSMEMBRANE PROTEIN WITH EGF LIKE AND TWO FOLLISTATIN LIKE DOMAIN; UNCLASSIFIED DRUG; VEDOTIN;

ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; AREA UNDER THE CURVE; ARTICLE; BLADDER; CONJUGATE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG RETENTION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; INTERNALIZATION; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN TARGETING; RADIOACTIVITY; RADIOIODINATION; SIGNAL NOISE RATIO; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TISSUE DISTRIBUTION; TUMOR LOCALIZATION; URINARY EXCRETION; X RAY ANALYSIS;

ANIMALS; ANTIGENS; CELL LINE, TUMOR; CYTOTOXINS; HETEROCYCLIC COMPOUNDS, 1-RING; IMMUNOCONJUGATES; MALE; MEMBRANE PROTEINS; MICE; MICE, SCID; NEOPLASM PROTEINS; NEOPLASMS; OLIGOPEPTIDES; PHARMACEUTICAL PREPARATIONS; TISSUE DISTRIBUTION;

EID: 84871597721     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02138.x     Document Type: Article

References (53)

1. Afar DE, Bhaskar V, Ibsen E, Breinberg D, Henshall SM, Kench JG, et al,. (2004). Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer. Mol Cancer Ther 3: 921-932.
2. Alley SC, Benjamin DR, Jeffrey SC, Okeley NM, Meyer DL, Sanderson RJ, et al,. (2008). Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem 19: 759-765.
3. Alley SC, Zhang X, Okeley NM, Anderson M, Law CL, Senter PD, et al,. (2009). The pharmacologic basis for antibody-auristatin conjugate activity. J Pharmacol Exp Ther 330: 932-938.
4. Austin CD, Wen X, Gazzard L, Nelson C, Scheller RH, Scales SJ, (2005). Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates. Proc Natl Acad Sci U S A 102: 17987-17992.
5. Bai RL, Pettit GR, Hamel E, (1990). Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J Biol Chem 265: 17141-17149.
6. Boswell CA, Brechbiel MW, (2007). Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. Nucl Med Biol 34: 757-778.
7. Boswell CA, Ferl GZ, Mundo EE, Schweiger MG, Marik J, Reich MP, et al,. (2010a). Development and evaluation of a novel method for preclinical measurement of tissue vascular volume. Mol Pharmaceutics 7: 1848-1857.
8. Boswell CA, Tesar DB, Mukhyala K, Theil FP, Fielder PJ, Khawli LA, (2010b). Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem 21: 2153-2163.
9. Boswell CA, Ferl GZ, Mundo EE, Bumbaca D, Schweiger MG, Theil FP, et al,. (2011a). Effects of anti-VEGF on predicted antibody biodistribution: roles of vascular volume, interstitial volume, and blood flow. PLoS ONE 6: e17874.
10. Boswell CA, Mundo EE, Zhang C, Bumbaca D, Valle N, Kozak K, et al,. (2011b). Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. Bioconjug Chem 22: 1994-2004.
11. Boswell CA, Bumbaca D, Fielder PJ, Khawli LA, (2012a). Compartmental tissue distribution of antibody therapeutics: experimental approaches and interpretations. AAPS J 14: 612-618.
12. 111In-labeled anti-TENB2 antibody-drug conjugate. J Nucl Med 53: 1454-1461.
13. Bumbaca D, Xiang H, Boswell CA, Port RE, Stainton SL, Mundo EE, et al,. (2011). Maximizing anti-neuropilin-1 tumour exposure requires saturation of non-tumour tissue antigenic sinks in mice. Br J Pharmacol 10: 1476-5381.
14. Burris HA, (2011). Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. Expert Opin Biol Ther 11: 807-819.
15. Carter PJ, Senter PD, (2008). Antibody-drug conjugates for cancer therapy. Cancer J 14: 154-169.
16. Chames P, Van Regenmortel M, Weiss E, Baty D, (2009). Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 157: 220-233.
17. Corey E, Vessella RL, (2007). Xenograft models of human prostate cancer. In:, Chung LWK, Isaacs WB, Simons JW, (eds). Prostate Cancer: Biology, Genetics, and the New Therapeutics, 2nd edn. Humana Press: Totowa, NJ, pp. 3-31.
18. Corey E, Quinn JE, Vessella RL, (2003). A novel method of generating prostate cancer metastases from orthotopic implants. Prostate 56: 110-114.
19. Davies B, Morris T, (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10: 1093-1095.
20. Denmeade SR, Isaacs JT, (2002). A history of prostate cancer treatment. Nat Rev Cancer 2: 389-396.
21. Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, Elkins K, et al,. (2009). Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood 114: 2721-2729.
22. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al,. (2003). Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 21: 778-784.
23. Doronina SO, Bovee TD, Meyer DW, Miyamoto JB, Anderson ME, Morris-Tilden CA, et al,. (2008). Novel peptide linkers for highly potent antibody-auristatin conjugate. Bioconjug Chem 19: 1960-1963.
24. Ducry L, Stump B, (2010). Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem 21: 5-13.
25. Feldman BJ, Feldman D, (2001). The development of androgen-independent prostate cancer. Nat Rev Cancer 1: 34-45.
26. Foyil KV, Bartlett NL, (2011). Brentuximab vedotin for the treatment of CD30+ lymphomas. Immunotherapy 3: 475-485.
27. Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al,. (2003). cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102: 1458-1465.
28. Glynne-Jones E, Harper ME, Seery LT, James R, Anglin I, Morgan HE, et al,. (2001). TENB2, a proteoglycan identified in prostate cancer that is associated with disease progression and androgen independence. Int J Cancer 94: 178-184.
29. Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT, (2007). Imaging prostate cancer: a multidisciplinary perspective. Radiology 243: 28-53.
30. Jemal A, Siegel R, Xu J, Ward E, (2010). Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
31. Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, et al,. (2008). Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 26: 925-932.
32. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
33. Koochekpour S, Zhuang YJ, Beroukhim R, Hsieh CL, Hofer MD, Zhau HE, et al,. (2005). Amplification and overexpression of prosaposin in prostate cancer. Genes Chromosomes Cancer 44: 351-364.
34. Lewis MR, Kao JY, Anderson AL, Shively JE, Raubitschek A, (2001). An improved method for conjugating monoclonal antibodies with N- hydroxysulfosuccinimidyl DOTA. Bioconjug Chem 12: 320-324.
35. Lin GA, Aaronson DS, Knight SJ, Carroll PR, Dudley RA, (2009a). Patient decision aids for prostate cancer treatment: a systematic review of the literature. CA Cancer J Clin 59: 379-390.
36. Lin K, Lou T, Ferl G, Leipold D, Graham R, Kozak KR, et al,. (2009b). Cross-species pharmacokinetic characterization of antibody drug conjugate TenB2-vc-E to understand target biology. AAPS Meeting Abstracts 2009.
37. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
38. Mandler R, Kobayashi H, Hinson ER, Brechbiel MW, Waldmann TA, (2004). Herceptin-geldanamycin immunoconjugates: pharmacokinetics, biodistribution, and enhanced antitumor activity. Cancer Res 64: 1460-1467.
39. Meares CF, McCall MJ, Reardan DT, Goodwin DA, Diamanti CI, McTigue M, (1984). Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal Biochem 142: 68-78.
40. Michaelson MD, Cotter SE, Gargollo PC, Zietman AL, Dahl DM, Smith MR, (2008). Management of complications of prostate cancer treatment. CA Cancer J Clin 58: 196-213.
41. Pastuskovas CV, Mundo EE, Williams SP, Nayak TK, Ho J, Ulufatu S, et al,. (2012). Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model. Mol Cancer Ther 11: 752-762.
42. Perera RM, Zoncu R, Johns TG, Pypaert M, Lee FT, Mellman I, et al,. (2007). Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody. Neoplasia 9: 1099-1110.
43. Ravizzini G, Turkbey B, Kurdziel K, Choyke PL, (2009). New horizons in prostate cancer imaging. Eur J Radiol 70: 212-226.
44. Regino CA, Wong KJ, Milenic DE, Holmes EH, Garmestani K, Choyke PL, et al,. (2009). Preclinical evaluation of a monoclonal antibody (3C6) specific for prostate-specific membrane antigen. Curr Radiopharm 2: 9-17.
45. Rogers BE, Franano FN, Duncan JR, Edwards WB, Anderson CJ, Connett JM, et al,. (1995). Identification of metabolites of 111In- diethylenetriaminepentaacetic acid-monoclonal antibodies and antibody fragments in vivo. Cancer Res 55 (Suppl. 23): 5714s-5720s.
46. Rosenthal SA, Sandler HM, (2010). Treatment strategies for high-risk locally advanced prostate cancer. Nat Rev Urol 7: 31-38.
47. Senter PD, (2009). Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 13: 235-244.
48. Shepard DR, Raghavan D, (2009). Innovations in the systemic therapy of prostate cancer. Nat Rev Clin Oncol 7: 13-21.
49. Stephan JP, Chan P, Lee C, Nelson C, Elliott JM, Bechtel C, et al,. (2008). Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination. Bioconjug Chem 19: 1673-1683.
50. Teicher BA, (2009). Antibody-drug conjugate targets. Curr Cancer Drug Targets 9: 982-1004.
51. Zhao XY, Schneider D, Biroc SL, Parry R, Alicke B, Toy P, et al,. (2005). Targeting tomoregulin for radioimmunotherapy of prostate cancer. Cancer Res 65: 2846-2853.
52. Zhao XY, Liu HL, Liu B, Willuda J, Siemeister G, Mahmoudi M, et al,. (2008). Tomoregulin internalization confers selective cytotoxicity of immunotoxins on prostate cancer cells. Transl Oncol 1: 102-109.
53. Zheng B, Fuji RN, Elkins K, Yu SF, Fuh FK, Chuh J, et al,. (2009). In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates. Mol Cancer Ther 8: 2937-2946.